Someone stopping these medications doesnt have the same control over their obesity, and their weight can increase. What to expect Nearly 12% of Americans about one in eight have used GLP-1 drugs for weight loss, according to a 2025 report from RAND, a nonprofit research organization
The most common adverse reactions based on clinical trial data (nausea, diarrhea, reduced appetite) are generally manageable
Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with alcohol use disorder (AUD) and either type 2 diabetes or obesity who started a newer GLP-1 RA (semaglutide, tirzepatide) to similar individuals starting alternative medications
However, before starting Medicare with a Part D policy (P.B
Medication leaking back out Sometimes after removing the needle, a small amount of clear fluid appears at the injection site
It was one of the rarer side effects reported in trials for semaglutide (Ozempic) and tirzepatide
